The 4 biggest pharma market access stories of 2019What events have defined the market access landscape in 2019, and what trends will shape 2020? We dive Share XThe 4 biggest pharma market access stories of 2019https://pharmaphorum.com/views-analysis-market-access/the-4-biggest-pharma-market-access-stories-of-2019/
An alternative set of metrics for the UK’s pricing and access dealLeela Barham takes a look at alternative ways pharma and the UK government could measure progress for the Share XAn alternative set of metrics for the UK’s pricing and access dealhttps://pharmaphorum.com/views-and-analysis/an-alternative-set-of-metrics-for-the-uks-pricing-and-access-deal/
Pharma prepares for Brexit as Tories win election majorityBoris Johnson’s Conservatives have won the UK’s general election with a large majority, leaving the industry preparing for Share XPharma prepares for Brexit as Tories win election majorityhttps://pharmaphorum.com/news/pharma-prepares-for-brexit-as-tories-win-election-majority/
Pharma fury as Trump’s team reneges on biologic patent rules in trade talksA key part of president Donald Trump’s strategy to cut drug prices was to attack global “freeloading” for Share XPharma fury as Trump’s team reneges on biologic patent rules in trade talkshttps://pharmaphorum.com/news/pharma-fury-as-trumps-team-reneges-on-biologic-patent-rules-in-trade-talks/
How does prevalence affect pricing of rare disease drugs?New research from CRA looks at the relationship between rarity of a disease and the price countries are Share XHow does prevalence affect pricing of rare disease drugs?https://pharmaphorum.com/views-analysis-market-access/prevalence-pricing-rare-disease-drugs/
Nine for 2019: how did we do on our predictions, and what does this mean for 2020?Year-ends prompt reflection, both on what’s happened in the last 12 months and on the year ahead. At Share XNine for 2019: how did we do on our predictions, and what does this mean for 2020?https://pharmaphorum.com/views-and-analysis/nine-for-2019-2020/
Drugs firms make massive discounts to get reimbursement in ChinaRoche and Novartis are among the pharmaceuticals companies who have agreed to cut prices of some of their Share XDrugs firms make massive discounts to get reimbursement in Chinahttps://pharmaphorum.com/news/drugs-firms-make-massive-discounts-to-get-reimbursement-in-china/
Trump’s reps ‘pushed hard’ for UK drug price reforms, leaked documents showRepresentatives of the Trump administration have “pushed hard” for pro-US drug pricing reforms in free trade negotiations with Share XTrump’s reps ‘pushed hard’ for UK drug price reforms, leaked documents showhttps://pharmaphorum.com/news/trump-administration-pushed-hard-for/
Conservatives shy away from drug price debate in election manifestoThe Conservative Party has pledged to encourage R&D in the UK’s life science industry should it win the Share XConservatives shy away from drug price debate in election manifestohttps://pharmaphorum.com/news/conservatives-shy-away-from-drug-price-debate-in-election-manifesto/
